Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuation
Torrent Pharma will acquire a controlling stake in JB Chemicals from KKR. The deal values JB Chemicals at Rs 25,689 crore. This merger will elevate Torrent to fifth position in the Indian pharmaceutical market. KKR is expected to gain a fivefold return on its 2020 investment. The combined entity aims for significant revenue and profitability growth.
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of Rs 25,689 crore ($3 billion). The deal, which will see a merger of the two entities, is among the biggest in the Indian pharmaceutical sector and brings to an end year-long negotiations. They had come close to a deal last year but couldn't agree on valuation at the time.With the acquisition of JB Chemicals, Torrent will move up to fifth rank by market share in the $26 billion Indian pharmaceutical market ahead of Alkem and Intas Pharma. ET had on June 29 been the first to report on the merger details.The deal was announced following a marathon meeting of Torrent Pharma's board of directors on Sunday.That's against the stock's Friday close of Rs 1,792. Torrent will also acquire up to 2.8% equity from certain employees of JB Chemicals at the Rs 1,600 apiece. The second part of the deal will follow amerger between Torrent and JB Chemicals through a scheme of arrangement. As per the approval by the two boards, upon the merger, every shareholder holding 100 shares in JB Chemicals will get 51 shares of Torrent. KKR had been the first to seek a restart of negotiations, according to the people cited above. Even at the discounted price, it will end with a fivefold return on what it paid to acquire JB Chemicals in 2020.Torrent Pharma posted FY25 revenue of Rs 11,500 crore, of which the Indian market accounted for Rs 6,393 crore. JB Chemicals recorded total FY25 sales of Rs 3,918 crore, of which the Indian market accounted for Rs 2,269 crore, growing at 20% over the previous year.Over the last decade, Torrent has grown inorganically with a string of deals that included skincare drugs maker Curatio in 2022 and more recently a range of anti-diabetes drugs from Boehringer Ingelheim. Apress statement from Torrent Pharma said the transaction marks a significant step in its ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO (contract development and manufacturing) capabilities. The deal is a strong fit for Torrent and complements its India presence, helping it move into the promising field of contract manufacturing besides allowing for market synergy, an analyst said. 'Torrent has a proven record of making deals work successfully,' the person added.The company will get access to leading brands in the chronic segment and entry into untapped therapeutic areas such as ophthalmology. Torrent said it will derive operational synergies across multiple business functions. 'We are pleased to have on board the JB Chemicals heritage and build on the platform for the future,' said Torrent Pharma executive chairman Samir Mehta. 'Torrent's deep India presence and JB Chemicals' fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability.'For KKR, this follows strong investment activity in India, where the buyout group has deployed more than $2 billion in private equity investments in the past year alone, in addition to a recent $600 million financing of Manipal Group. This also builds on KKR's strong healthcare track record, including a fivefold return in Max Healthcare in 2022 that had also marked the largest block deal by a private equity firm in India, and recent investments in healthcare, including Healthcare Global Enterprises, BMH (Baby Memorial Hospital), Healthium and Infinx.JB Chemicals said it had built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. 'As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets,' said Nikhil Chopra, chief executive officer and whole time director of JB Chemicals.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
11 minutes ago
- Business Standard
Sony India targets ₹10,000 crore revenue in 3 years, led by audio
Consumer electronics maker Sony India is eyeing a topline of ₹10,000 crore in the coming two to three years, as the share from audio categories continues to rise, a top company executive said on Monday. India remains the fourth-largest market by revenue for Sony Corporation globally. 'The contribution of the audio segment is growing by a couple of percentage points each year. In the coming year, we expect to clock double-digit growth and reach overall revenues of ₹10,000 crore in the midterm,' said Sunil Nayyar, Managing Director, Sony India, at a media roundtable during the launch of two new soundbar models as part of its BRAVIA Theatre home entertainment line. Audio and imaging will be the two big drivers of growth toward the company's revenue goals, Nayyar said, adding that Sony is also working to create fresh demand in the imaging segment. 'We want to change the culture of clicking photos on the phone, which is how it used to be earlier,' he said. Audio currently contributes 13–15 per cent to the company's overall revenue, while televisions remain its largest business, accounting for 55–60 per cent. Digital imaging makes up 20–22 per cent, with the remaining revenue coming from products such as the PlayStation. On the issue of rare earth magnet availability, amid China's trade restrictions, company officials said they are not facing any supply challenges. Sony India witnessed double-digit growth in the last financial year. In FY23–24, the company recorded revenue of ₹7,664 crore. Regarding product performance, Nayyar said the TV segment saw growth in the over-55-inch category, while other segments within the category remained stagnant. 'The over-55-inch segment is a big segment and is growing at a high rate,' he noted. Meanwhile, PlayStation sales have quadrupled in the last three years, signalling a rising gaming culture in India. Speaking on quick commerce, where Sony made headlines by selling the PS5, Nayyar said the emerging channel is promising. 'The channel, although very new, has shown promise. We saw traction for the PlayStation and are seeing promise in headphones and speakers too. It is a small business currently but can become bigger as we move forward,' he said. Despite the entry of new players into the Indian market, the company remains focused on maintaining its premium positioning. 'We continue to be a premium brand and are not competing with mass-market price points. We make sure we are reasonably premium, can justify the value proposition to customers, and remain their go-to premium brand,' Nayyar added.
&w=3840&q=100)
Business Standard
11 minutes ago
- Business Standard
Akasa Air's net loss widens to ₹1,983 crore in FY25 as costs, delays rise
Akasa Air's standalone net loss rose 18.7 per cent year-on-year (YoY) to approximately ₹1,983 crore in the financial year 2024–25, driven by rising employee costs, aircraft maintenance and airport charges, and a sharp increase in forex expenses, sources privy to the development told Business Standard. While Akasa slipped further into the red, the other three major Indian airlines — IndiGo, SpiceJet and Air India — fared much better in FY25. IndiGo remained highly profitable despite a slight year-on-year decline in profit, SpiceJet returned to the black, and Air India significantly reduced its losses while turning operationally profitable. Responding to queries on its FY25 results, an Akasa Air spokesperson said the airline does not comment on speculation, but added: 'It is important to note that the foundational years of any airline are dedicated to investing in its people, fleet, training, operating infrastructure, and network, and hence no airline registers P&L (net) profits in these years. Running an airline is a business of fixed costs and needs some scale before we turn profitable. This is neither surprising nor unanticipated. Our robust business plan provides for these losses.' The spokesperson added that Akasa remains 'net cash positive' at the operating level, and that 'financially, we are ahead of our plans and our investors have always believed in the long-term vision and fundamentals of Akasa Air'. The airline, which began operations in August 2022, saw employee costs rise by 36 per cent YoY in FY25, sources stated. Maintenance expenses grew by 26.6 per cent YoY, while forex costs surged by 181 per cent YoY, they added. Airport charges have increased 40.9 per cent YoY in FY25. Meanwhile, the airline is also seeing a leadership churn in recent months. Ajit Bhagchandani, Vice-President (In-Flight Services), stepped down recently. Confirming this, the airline spokesperson said: 'Mr Ajit Bhagchandani has decided to move on due to personal reasons. We respect his decision and are grateful to Ajit for his contribution in building Akasa.' As first reported by Business Standard on 26 May, three other senior executives had either resigned or were serving notice — Rishabh Dev, Head of Long-Term Operations and Strategy; Amol Mane, Vice-President of Aircraft Acquisition and Leasing; and Vineet Mishra, Deputy General Manager for Catering. This leadership churn comes at a time when the airline's expansion has visibly slowed. After rapidly ramping up from 36 weekly flights in August 2022 to 945 by June 2023, Akasa has managed to increase its weekly services by just 13.2 per cent over the past two years, operating 1,070 weekly flights as of June 2025, Cirium data shows. A major constraint has been delayed aircraft deliveries from Boeing. Out of 226 planes ordered, only 30 have been inducted so far. While 24 of them were added between June 2022 and June 2024, just six arrived in the past year, leaving a large section of the airline's pilot workforce underutilised and pushing up costs. The airline addressed this pilot issue in its response to the newspaper. 'We currently have 775 pilots hired to fly and despite the changes in the aircraft delivery schedules, more than 78 per cent of our pilots have begun to accumulate flying hours, which is a significant increase from 60 per cent in December 2024. By the end of this calendar year, 100 per cent of our pilots will be accumulating flying hours,' the spokesperson said. The spokesperson also reaffirmed the airline's confidence in its aircraft supplier. 'Our relationship with Boeing remains strong and collaborative. We have received three aircraft deliveries in the last six weeks, taking our fleet strength to 30, and are confident about receiving our planned deliveries this year.' Akasa said it increased its available seat kilometres (ASKs) by about 40 per cent in FY25 and is targeting similar year-on-year growth in the current fiscal. ASK is a standard measure of airline capacity, calculated by multiplying the number of seats available by the distance flown. 'We will receive 196 more aircraft over seven years. Aircraft deliveries will naturally translate to more SLB gains, and more cash flow. Our cost structure is well thought through, and we are incredibly disciplined in how we allocate capital,' the spokesperson said. SLB refers to sale-and-leaseback transactions, where the airline sells a newly delivered aircraft to a lessor and then leases it back — generating upfront cash while still retaining operational use of the plane. IndiGo, India's largest airline, posted a net profit of ₹7,258 crore in FY25. SpiceJet reported a standalone net profit of ₹61.9 crore for the year, marking its first full-year profit in seven years. Air India, while not disclosing exact figures, informed employees that it had turned operationally profitable in FY25, with its overall losses decreasing significantly.
&w=3840&q=100)
Business Standard
11 minutes ago
- Business Standard
Apollo Hospitals to list digital health, pharmacy unit in 18-21 months
Indian hospital chain Apollo Hospitals said on Monday it will spin off and separately list its digital health and pharmacy unit within 18 to 21 months, as part of a reorganisation. Apollo shareholders will receive 195.2 shares of the spun-off entity for every 100 shares they currently own. The hospital operator will retain a 15 per cent stake in the entity, which it is yet to be named, and will also have its nominee on the board of the new company. Apollo Hospitals expects the new entity, which would also include pharmacy distributor Keimed, to clock revenue of about 250 billion rupees ($2.92 billion) for the year ending March 2027, and earnings before interest, taxes, depreciation and amortisation margin of roughly 7 per cent for the same period.
